Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone Augmentation in MDD
NCT00633399Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2008
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Ziprasidone + SSRI with Placebo + SSRI (2 arms). Primary endpoint: Response Rates (50% Decrease in HAM-D-17 Scores) at 8 weeks. Started Jul 2008; status: completed.
02
Drugs
ziprasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00633399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633399.